FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Machinatan	D C	20540	
Nashington,	D.C.	20049	

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP
	OI OII/AITOEO	III DEIIEI IOIAE	O 1111 - 1101 III

OMB APPROVAL									
OMB Number: 3235-0									
Estimated average burden									
hours per respons	e 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Terrillion Scott					2. Issuer Name and Ticker or Trading Symbol Cara Therapeutics, Inc. [CARA])% Owner			
(Last)	•	rst) (MAPEUTICS, INC	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 02/01/2024						X SE	below	er (give title v) CHIEF CO	MPL	Other (below) LIANCE &	·				
400 ATL	ANTIC ST	REET, SUITE 5	00		4. If A	Amend	ment,	Date o	f Origina	al Filed	d (Month/Da	y/Year)		6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) STAMFO	ORD C	Γ 0	6901										X		filed by On filed by Mo on		•			
(City)	(City) (State) (Zip) Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												nded to							
		Table	I - No	n-Deriva	tive S	Secui	rities	Acq	uired,	Dis	posed of	or B	enefic	ially	Own	ed				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D.			Execution Date,				es Acquired (A) Of (D) (Instr. 3, 4		4 and Securi Benefi Owned		ties cially Following	Forn (D) o	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership						
						Code V Amount (A) or (D)					Pric	e	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)			
Common	Stock			02/01/2	2024				A		13,500(1)) A	\$	\$0 102,063 D		D				
		Tal									osed of, o				Owne	d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, Transaction of		rative rities ired r osed)	6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date			Amount of Securities Securities		Der Sec	8. Price of Derivative Security (Instr. 5) 8. Ni deriv Security (Instr. 5) 9. Ni deriv Security Security Security (Instr. 5) 8. Price of Derivative Security Security (Instr. 5)		у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				

Explanation of Responses:

1. Represents the number of shares that vested under a performance-based restricted stock unit award (the "Award") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals.

> /s/ Darren DeStefano, Attorney-in-Fact

02/05/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.